Drugs’ “Widely Available Market Price” To Be Calculated Using 10 Sources
Executive Summary
The HHS Office of Inspector General will collect market price data from 10 different sources to determine the "widely available market price" of drugs
You may also be interested in...
CMS Updates 2005 Part B Payment Rates; Gemzar ASP Increases By 7.3%
Lilly has reversed a 7% price cut for the oncologic Gemzar ahead of the 2005 transition to average sales price-based reimbursement under Medicare Part B
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials